IgA nephropathy frequently leads to progressive CKD. Although interest surrounds use of immunosuppressive agents added to standard therapy, several recent studies have questioned efficacy of these agents. Depleting antibody-producing B cells potentially offers a new therapy. In this open label, multicenter study conducted over 1-year follow-up, we randomized 34 adult patients with biopsy-proven IgA nephropathy and proteinuria >1 g/d, maintained on angiotensin-converting enzyme inhibitors or angiotensin receptor blockers with well controlled BP and eGFR<90 ml/min per 1.73 m2, to receive standard therapy or rituximab with standard therapy. Primary outcome measures included change in proteinuria and change in eGFR. Median baseline serum creatinine level (range) was 1.4 (0.8-2.4) mg/dl, and proteinuria was 2.1 (0.6-5.3) g/d. Treatment with rituximab depleted B cells and was well tolerated. eGFR did not change in either group. Rituximab did not alter the level of proteinuria compared with that at baseline or in the control group; three patients in each group had ≥50% reduction in level of proteinuria. Serum levels of galactose-deficient IgA1 or antibodies against galactose-deficient IgA1 did not change. In this trial, rituximab therapy did not significantly improve renal function or proteinuria assessed over 1 year. Although rituximab effectively depleted B cells, it failed to reduce serum levels of galactose-deficient IgA1 and antigalactose-deficient IgA1 antibodies. Lack of efficacy of rituximab, at least at this stage and severity of IgA nephropathy, may reflect a failure of rituximab to reduce levels of specific antibodies assigned salient pathogenetic roles in IgA nephropathy.

Department of Immunology Faculty of Medicine and Dentistry Palacky University and University Hospital Olomouc Czech Republic

Department of Laboratory Medicine and Pathology and

Departments of Microbiology and

Division of Biomedical Statistics and Informatics Department of Health Sciences Research Mayo Clinic Rochester Minnesota

Division of Nephrology and Hypertension

Division of Nephrology and Hypertension Columbia University Medical Center New York New York

Division of Nephrology and Hypertension Stanford University Stanford California

Division of Nephrology Ohio State University Columbus Ohio

Division of Nephrology University of Tennessee Chattanooga Tennessee; and

Medicine University of Alabama at Birmingham Birmingham Alabama

Komentář v

Nat Rev Nephrol. 2017 Mar;13(3):138-140. doi: 10.1038/nrneph.2016.188. PubMed

Zobrazit více v PubMed

Li LS, Liu ZH: Epidemiologic data of renal diseases from a single unit in China: Analysis based on 13,519 renal biopsies. Kidney Int 66: 920–923, 2004 PubMed

Zaza G, Bernich P, Lupo A; “Triveneto” Register of Renal Biopsies (TVRRB) : Incidence of primary glomerulonephritis in a large North-Eastern Italian area: A 13-year renal biopsy study. Nephrol Dial Transplant 28: 367–372, 2013 PubMed

Barratt J, Feehally J: IgA nephropathy. J Am Soc Nephrol 16: 2088–2097, 2005 PubMed

Barbour SJ, Reich HN: Risk stratification of patients with IgA nephropathy. Am J Kidney Dis 59: 865–873, 2012 PubMed

Boyd JK, Cheung CK, Molyneux K, Feehally J, Barratt J: An update on the pathogenesis and treatment of IgA nephropathy. Kidney Int 81: 833–843, 2012 PubMed

D’Amico G: Natural history of idiopathic IgA nephropathy: Role of clinical and histological prognostic factors. Am J Kidney Dis 36: 227–237, 2000 PubMed

Wang W, Chen N: Treatment of progressive IgA nephropathy: An update. Contrib Nephrol 181: 75–83, 2013 PubMed

Pozzi C, Andrulli S, Del Vecchio L, Melis P, Fogazzi GB, Altieri P, Ponticelli C, Locatelli F: Corticosteroid effectiveness in IgA nephropathy: Long-term results of a randomized, controlled trial. J Am Soc Nephrol 15: 157–163, 2004 PubMed

Lv J, Zhang H, Chen Y, Li G, Jiang L, Singh AK, Wang H: Combination therapy of prednisone and ACE inhibitor versus ACE-inhibitor therapy alone in patients with IgA nephropathy: A randomized controlled trial. Am J Kidney Dis 53: 26–32, 2009 PubMed

Rauen T, Eitner F, Fitzner C, Sommerer C, Zeier M, Otte B, Panzer U, Peters H, Benck U, Mertens PR, Kuhlmann U, Witzke O, Gross O, Vielhauer V, Mann JF, Hilgers RD, Floege J; STOP-IgAN Investigators : Intensive supportive care plus immunosuppression in IgA nephropathy. N Engl J Med 373: 2225–2236, 2015 PubMed

Tang SC, Tang AW, Wong SS, Leung JC, Ho YW, Lai KN: Long-term study of mycophenolate mofetil treatment in IgA nephropathy. Kidney Int 77: 543–549, 2010 PubMed

Hogg RJ, Bay RC, Jennette JC, Sibley R, Kumar S, Fervenza FC, Appel G, Cattran D, Fischer D, Hurley RM, Cerda J, Carter B, Jung B, Hernandez G, Gipson D, Wyatt RJ: Randomized controlled trial of mycophenolate mofetil in children, adolescents, and adults with IgA nephropathy. Am J Kidney Dis 66: 783–791, 2015 PubMed

Suzuki H, Kiryluk K, Novak J, Moldoveanu Z, Herr AB, Renfrow MB, Wyatt RJ, Scolari F, Mestecky J, Gharavi AG, Julian BA: The pathophysiology of IgA nephropathy. J Am Soc Nephrol 22: 1795–1803, 2011 PubMed PMC

Lai KN, Tang SCW, Schena FP, Novak J, Tomino Y, Foggo AB, Glassock RJ: IgA nephropathy. Nat Rev Dis Primers 2016 Feb 11: 16001. doi: 10.1038/nrdp.2016.1 PubMed

Berthoux F, Suzuki H, Thibaudin L, Yanagawa H, Maillard N, Mariat C, Tomino Y, Julian BA, Novak J: Autoantibodies targeting galactose-deficient IgA1 associate with progression of IgA nephropathy. J Am Soc Nephrol 23: 1579–1587, 2012 PubMed PMC

Zhao N, Hou P, Lv J, Moldoveanu Z, Li Y, Kiryluk K, Gharavi AG, Novak J, Zhang H: The level of galactose-deficient IgA1 in the sera of patients with IgA nephropathy is associated with disease progression. Kidney Int 82: 790–796, 2012 PubMed PMC

Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, Kallenberg CG, St Clair EW, Turkiewicz A, Tchao NK, Webber L, Ding L, Sejismundo LP, Mieras K, Weitzenkamp D, Ikle D, Seyfert-Margolis V, Mueller M, Brunetta P, Allen NB, Fervenza FC, Geetha D, Keogh KA, Kissin EY, Monach PA, Peikert T, Stegeman C, Ytterberg SR, Specks U; RAVE-ITN Research Group : Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 363: 221–232, 2010 PubMed PMC

Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, Stevens RM, Shaw T: Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 350: 2572–2581, 2004 PubMed

Fervenza FC, Abraham RS, Erickson SB, Irazabal MV, Eirin A, Specks U, Nachman PH, Bergstralh EJ, Leung N, Cosio FG, Hogan MC, Dillon JJ, Hickson LJ, Li X, Cattran DC; Mayo Nephrology Collaborative Group : Rituximab therapy in idiopathic membranous nephropathy: A 2-year study. Clin J Am Soc Nephrol 5: 2188–2198, 2010 PubMed PMC

Pindi Sala T, Michot JM, Snanoudj R, Dollat M, Estève E, Marie B, Taoufik Y, Delfraissy JF, Lazure T, Lambotte O: Successful outcome of a corticodependent Henoch-Schönlein purpura adult with rituximab. Case Rep Med 2014: 619218, 2014 PubMed PMC

Donnithorne KJ, Atkinson TP, Hinze CH, Nogueira JB, Saeed SA, Askenazi DJ, Beukelman T, Cron RQ: Rituximab therapy for severe refractory chronic Henoch-Schönlein purpura. J Pediatr 155: 136–139, 2009 PubMed

Cattran DC, Coppo R, Cook HT, Feehally J, Roberts IS, Troyanov S, Alpers CE, Amore A, Barratt J, Berthoux F, Bonsib S, Bruijn JA, D’Agati V, D’Amico G, Emancipator S, Emma F, Ferrario F, Fervenza FC, Florquin S, Fogo A, Geddes CC, Groene HJ, Haas M, Herzenberg AM, Hill PA, Hogg RJ, Hsu SI, Jennette JC, Joh K, Julian BA, Kawamura T, Lai FM, Leung CB, Li LS, Li PK, Liu ZH, Mackinnon B, Mezzano S, Schena FP, Tomino Y, Walker PD, Wang H, Weening JJ, Yoshikawa N, Zhang H; Working Group of the International IgA Nephropathy Network and the Renal Pathology Society : The Oxford classification of IgA nephropathy: Rationale, clinicopathological correlations, and classification. Kidney Int 76: 534–545, 2009 PubMed

Yuling H, Ruijing X, Xiang J, Yanping J, Lang C, Li L, Dingping Y, Xinti T, Jingyi L, Zhiqing T, Yongyi B, Bing X, Xinxing W, Youxin J, Fox DA, Lundy SK, Guohua D, Jinquan T: CD19+CD5+ B cells in primary IgA nephropathy. J Am Soc Nephrol 19: 2130–2139, 2008 PubMed PMC

Lomax-Browne HJ, Visconti A, Pusey CD, Cook HT, Spector TD, Pickering MC, Falchi M: IgA1 glycosylation is heritable in healthy twins [published online ahead of print June 16, 2016]. J Am Soc Nephrol PubMed PMC

Gharavi AG, Moldoveanu Z, Wyatt RJ, Barker CV, Woodford SY, Lifton RP, Mestecky J, Novak J, Julian BA: Aberrant IgA1 glycosylation is inherited in familial and sporadic IgA nephropathy. J Am Soc Nephrol 19: 1008–1014, 2008 PubMed PMC

Suzuki H, Raska M, Yamada K, Moldoveanu Z, Julian BA, Wyatt RJ, Tomino Y, Gharavi AG, Novak J: Cytokines alter IgA1 O-glycosylation by dysregulating C1GalT1 and ST6GalNAc-II enzymes. J Biol Chem 289: 5330–5339, 2014 PubMed PMC

Novak J, Rizk D, Takahashi K, Zhang X, Bian Q, Ueda H, Ueda Y, Reily C, Lai LY, Hao C, Novak L, Huang ZQ, Renfrow MB, Suzuki H, Julian BA: New insights into the pathogenesis of IgA nephropathy. Kidney Dis (Basel) 1: 8–18, 2015 PubMed PMC

Leiper K, Martin K, Ellis A, Subramanian S, Watson AJ, Christmas SE, Howarth D, Campbell F, Rhodes JM: Randomised placebo-controlled trial of rituximab (anti-CD20) in active ulcerative colitis. Gut 60: 1520–1526, 2011 PubMed

Hoffman W, Lakkis FG, Chalasani G: B cells, antibodies, and more. Clin J Am Soc Nephrol 11: 137–154, 2016 PubMed PMC

Reich HN, Troyanov S, Scholey JW, Cattran DC; Toronto Glomerulonephritis Registry : Remission of proteinuria improves prognosis in IgA nephropathy. J Am Soc Nephrol 18: 3177–3183, 2007 PubMed

Berthelot L, Robert T, Vuiblet V, Tabary T, Braconnier A, Dramé M, Toupance O, Rieu P, Monteiro RC, Touré F: Recurrent IgA nephropathy is predicted by altered glycosylated IgA, autoantibodies and soluble CD89 complexes. Kidney Int 88: 815–822, 2015 PubMed

Moldoveanu Z, Wyatt RJ, Lee JY, Tomana M, Julian BA, Mestecky J, Huang WQ, Anreddy SR, Hall S, Hastings MC, Lau KK, Cook WJ, Novak J: Patients with IgA nephropathy have increased serum galactose-deficient IgA1 levels. Kidney Int 71: 1148–1154, 2007 PubMed

Suzuki H, Moldoveanu Z, Hall S, Brown R, Vu HL, Novak L, Julian BA, Tomana M, Wyatt RJ, Edberg JC, Alarcón GS, Kimberly RP, Tomino Y, Mestecky J, Novak J: IgA1-secreting cell lines from patients with IgA nephropathy produce aberrantly glycosylated IgA1. J Clin Invest 118: 629–639, 2008 PubMed PMC

Suzuki H, Fan R, Zhang Z, Brown R, Hall S, Julian BA, Chatham WW, Suzuki Y, Wyatt RJ, Moldoveanu Z, Lee JY, Robinson J, Tomana M, Tomino Y, Mestecky J, Novak J: Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneity. J Clin Invest 119: 1668–1677, 2009 PubMed PMC

Targeting APRIL in the Treatment of IgA Nephropathy

IgA nephropathy

The role of BAFF and APRIL in IgA nephropathy: pathogenic mechanisms and targeted therapies

Implications of rituximab pharmacokinetic and pharmacodynamic alterations in various immune-mediated glomerulopathies and potential anti-CD20 therapy alternatives

New Treatment Strategies for IgA Nephropathy: Targeting Plasma Cells as the Main Source of Pathogenic Antibodies

Emerging Modes of Treatment of IgA Nephropathy

Why Target the Gut to Treat IgA Nephropathy?